Back to Search
Start Over
Current and Emerging Approaches for Nonalcoholic Steatohepatitis Treatment
- Source :
- Gene Expression. 19:175-185
- Publication Year :
- 2019
- Publisher :
- Xia & He Publishing, 2019.
-
Abstract
- Nonalcoholic steatohepatitis (NASH) is the second leading cause of liver transplantation in the US with a high risk of liver-related morbidities and mortality. Given the global burden of NASH, development of appropriate therapeutic strategies is an important clinical need. Where applicable, lifestyle modification remains the primary recommendation for the treatment of NASH, even though such changes are difficult to sustain and even insufficient to cure NASH. Bariatric surgery resolves NASH in such patients where lifestyle modifications have failed, and is recommended for morbidly obese patients with NASH. Thus, pharmacotherapies are of high value for NASH treatment. Though no drug has been approved by the US Food and Drug Administration for treatment of NASH, substantial progress in pharmacological development has been made in the last few years. Agents such as vitamin E and pioglitazone are recommended in patients with NASH, and yet concerns about their side effects remain. Many agents targeting various vital molecules and pathways, including those impacting metabolic perturbations, inflammatory cascades, and oxidative stress, are in clinical trials for the treatment of NASH. Some agents have shown promising results in phase II or III clinical trials, but more studies are required to assess their long-term effects. Herein, we review the potential strategies and challenges in therapeutic approaches to treating NASH.
- Subjects :
- Drug
Nonalcoholic steatohepatitis
medicine.medical_specialty
media_common.quotation_subject
medicine.medical_treatment
Bariatric Surgery
Review
Morbidly obese
Liver transplantation
digestive system
Food and drug administration
03 medical and health sciences
0302 clinical medicine
Lifestyle modification
Non-alcoholic Fatty Liver Disease
Genetics
medicine
Animals
Humans
Hypoglycemic Agents
In patient
Healthy Lifestyle
Molecular Targeted Therapy
Intensive care medicine
Molecular Biology
media_common
business.industry
nutritional and metabolic diseases
digestive system diseases
Clinical trial
030220 oncology & carcinogenesis
030211 gastroenterology & hepatology
business
Subjects
Details
- ISSN :
- 10522166
- Volume :
- 19
- Database :
- OpenAIRE
- Journal :
- Gene Expression
- Accession number :
- edsair.doi.dedup.....e4b3a59d9ec392dc9663313185da1001